Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer

Cancer Prevention and Control

Volumn 2, Issue 4, 1998, Pages 179-190

  Rusthoven, J ^a   Bramwell, V ^a   Stephenson, B ^a   Anderson, E ^a   Broadfield, L ^a   Charbonneau, F ^a   Feld, R ^a   Findlay, B ^a   Iscoe, N ^a   Moore, M ^a   Nefsky, M ^a   Palmer Wickman, S ^a   Pater, J ^a   Puodziunas, A ^a   Stewart, D ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO;

ANTIBIOTIC THERAPY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NEUTROPENIA; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CANADA; CISPLATIN; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; META-ANALYSIS; NEOPLASMS; NEUTROPENIA; ODDS RATIO; QUALITY OF LIFE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0031710447     PISSN: 1206548X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)